Chemoprevention of head and neck cancer

Otolaryngology-Head and Neck Surgery

Volumn 122, Issue 5, 2000, Pages 728-735

  Armstrong, William B ^a   Meyskens, Frank L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; CAROTENOID; DAIDZEIN; GENISTEIN; INDOMETACIN; ISOFLAVONE; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT; POLYPHENOL; PROTEINASE INHIBITOR; RETINOID; RETINOL;

CANCER PREVENTION; CONJUNCTIVITIS; DIETARY INTAKE; DRUG INDUCED DISEASE; HEAD AND NECK CANCER; HUMAN; LEUKOPLAKIA; MOUTH CANCER; MUCOSA INFLAMMATION; NONHUMAN; PRECANCER; REVIEW; SOYBEAN; SQUAMOUS CELL CARCINOMA; TEA;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 0034031282     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1016/S0194-5998(00)70205-1     Document Type: Review

References (82)

1. Sarraf Al M LeBlanc M Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol 1998; 16: 1310–7.
2. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–90.
3. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17: 449–456.
4. Lippman SM, Spitz M, Trizna Z, et al. Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 1994; 74(Supplement):2719–25.
5. Jones AS, Morar P, Phillips DE, et al. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995; 75: 1343–53.
6. Shikhani AH, Matanoski GM, Jones MM, et al. Multiple primary malignancies in head and neck cancer. Arch Otolaryngol Head Neck Surg 1986; 112: 1172–9.
7. Califano J, Van der Riet P Westra W, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996; 56: 2488–92.
8. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 229–233.
9. Meyskens FL, Jr. Biology and intervention of the premalignant process. Cancer Bull 1991; 43: 475–480.
10. Bertram JS, Kolonel LN, Meyskens F. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987; 47: 3013–31.
11. Shaha AR. Cancer of the head and neck. In: Murphy GP Lawrence W Lenhard RE, editors. American Cancer Society textbook of clinical oncology. Atlanta: American Cancer Society; 1995. p. 355–377.
12. Vokes E, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993; 328: 184–194.
13. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21: 281–8.
14. Hsu TC, Cherry LM, Samaan NA. Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 1985; 17: 307–313.
15. Spitz MR, Fueger JJ, Beedingfield NA, et al. Chromosome sensitivity to bleomycin induced mutagenesis: An independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989; 49: 4626–8.
16. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994; 86: 1681–4.
17. Spitz MR, Lippman SM, Jiang H, et al. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 1998; 90: 243–5.
18. Cloos J, Spitz MR, Schantz SP, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 530–5.
19. Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89: 199–211.
20. Perera FP. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996; 88: 496–509.
21. Waldron CA, Shaver WG. Leukoplakia revisited: A clinicopathologic study of 3256 oral leukoplakias. Cancer 1975; 36: 1386–92.
22. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 1984; 53: 563–8.
23. Einhorn J, Wersall J. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer 1967; 20: 2189–93.
24. Kotwall C, Razack MS, Sako K, et al. Multiple primary cancers in squamous cell cancer of the head and neck. J Surg Oncol 1989; 40: 97–99.
25. Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 1953; 6: 963–8.
26. Bedi G, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 1996; 56: 2484–7.
27. Hong WK, Lippman SM. Cancer chemoprevention. J Natl Cancer Inst Monogr 1995; 17: 49–53.
28. Willett WC, MacMahon B. Diet and cancer—an overview. N Engl J Med 1984; 310: 633–8.
29. Willett WC, MacMahon B. Diet and cancer—an overview (second of two parts). N Engl J Med 1984; 310: 697–702.
30. Kelloff GJ, Malone WF, Boone CW, et al. Progress in applied chemoprevention research. Semin Oncol 1990; 17: 438–455.
31. Garewal HS, Meyskens FL, Jr. Chemoprevention of cancer. Hematol Oncol Clin North Am 1991; 5: 69–77.
32. Goodman GE. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives. Cancer Res 1992; 52(Supplement):2752s–7s.
33. Shin DM, Hittelman WN, Hong WK. Biomarkers in upper aerodigestive tract tumorigenesis: A review. Cancer Epidemiol Biomarkers Prev 1994; 3: 697–709.
34. Kim J, Shin DM. Biomarkers of squamous cell carcinoma of the head and neck. Histol Histopathol 1997; 12: 205–218.
35. Krinsky NI. Actions of carotenoids in biological systems. Annu Rev Nutr 1993; 13: 561–587.
36. Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42: 195–9.
37. Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol 1993; 3: 225–234.
38. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145–9.
39. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–35.
40. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 1996; 88: 1550–9.
41. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5.
42. Greenberg RE, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous cell cancers of the skin [published correction appears in N Engl J Med 1991; 325: 324]. N Engl J Med 1990;323:789–95.
43. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994; 331: 141–7.
44. Romney SL, Ho GYF, Palan PR, et al. Effects of beta carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997; 65: 483–492.
45. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (part 1). Cancer Treatment Reports 1987; 71: 391–405.
46. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (part II). Cancer Treatment Reports 1987; 71: 493–515.
47. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332: 1405–10.
48. Xu XC, Zile MH, Lippman SM, et al. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 1995; 55: 5507–11.
49. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501–5.
50. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795–801.
51. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. J Natl Cancer Inst 1994; 86: 140–1.
52. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Supplement 1993; 17F: 255–261.
53. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994; 54(Supplement):2032s–7s.
54. Han J, Jiao L, Lu Y, et al. Evaluation of N-4-(hydroxycarbo-phenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990; 4: 153–160.
55. De Vries N Pastorino U Van Zandwijk N. Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. Eur J Cancer B Oral Oncol 1994; 30B: 367–8.
56. DM90–094 MSS. Available at: http://143.111.31.72/Domino/ClinicalTrialsWP.nsf/4c0dfe3b163798fc862565fb0002f3ba/f0d33234cab629818625670b00509e34. Accessed January 29, 1999.
57. Agarwal R, Mukhtar H. Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol 1996; 401: 35–50.
58. The Indian US Head and Neck Cancer Cooperative Group. Green tea and leukoplakia. Am J Surg 1997; 174: 552–5.
59. Schantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997; 216: 275–282.
60. Blot WJ, Chow WH, McLaughlin JK. Tea and cancer: A review of the epidemiological evidence. Eur J Cancer Prev 1996; 5: 425–438.
61. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993; 85: 1038–49.
62. Stich HF. Teas and tea components as inhibitors of carcinogen formation in model systems and man. Prev Med 1992; 21: 377–384.
63. Benner SE, Winn RJ, Lippman SM, et al. Regression of oral leukoplakia with alpha-tocopherol: A community clinical oncology program chemoprevention study. J Natl Cancer Inst 1993; 85: 44–47.
64. Ondrey FG. Arachidonic acid metabolism: A primer for head and neck surgeons. Head Neck 1998; 20: 334–349.
65. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658–663.
66. Lupulescu A. Enhancement of carcinogenesis by prostaglandins in male albino Swiss mice. J Natl Cancer Inst 1978; 61: 97–106.
67. Spingarn A, Sacks PG, Kelley D, et al. Synergistic effects of 13-cis retinoic acid and arachidonic acid cascade inhibitors on growth of head and neck squamous cell carcinoma in vitro. Otolaryngol Head Neck Surg 1998; 118: 159–164.
68. Suen J, Atchley Simonton S. Spontaneous remission of head and neck cancer: A report of 5 cases. 4th International Conference on Head and Neck Cancer. Toronto, Canada; Jul 28-Aug 1, 1996.
69. Saleem Al T Ali ZS Qassab M. Skin cancers in xeroderma pigmentosum: Response to indomethacin and steroids. Lancet 1980; 2: 264–5.
70. Stoll BA. Indomethacin in breast cancer. Lancet 1973; 2: 384.
71. Keefe K, Meyskens FL, Jr. Cancer prevention. In: Abeloff MD Armitage JO Lichter AS, et al, editors. Clinical oncology. 2nd ed. New York: Churchill Livingstone; 2000. p. 318–365.
72. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis Part II. J Natl Cancer Inst 1998; 90: 1609–20.
73. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis part I. J Natl Cancer Inst 1998; 90: 1529–36.
74. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–614.
75. Michaluart P, Chan G, Boyle JO, et al. The feasibility of cyclooxygenase (COX) II inhibitor chemoprevention in head and neck cancer. American Society for Head and Neck Surgeons Annual Meeting. West Palm Beach (FL); May 14–16, 1998.
76. Kennedy AR. Prevention of carcinogenesis by protease inhibitors. Cancer Res 1994; 54(Supplement):1999s–2005s.
77. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83: 541–6.
78. Messina MJ, Persky V, Setchell KDR, et al. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113–131.
79. Kennedy AR. Chemopreventive agents: Protease inhibitors. Pharmacol Ther 1998; 78: 167–209.
80. Fournier DB, Erdman JW, Gordon GB. Soy, its components, and cancer prevention: A review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev 1998; 7: 1055–65.
81. Kennedy AR, Manzone H. Effects of protease inhibitors on levels of proteolytic activity in normal and pre-malignant cells and tissues. J Cell Biochem 1995; 22(Supplement):188–94.
82. Armstrong WB, Kennedy AR, Wan XS, et al. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000; 9: 43–47.